Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

ConclusionBinimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring KRAS mutations.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research